Explore 3 Stock Ideas & Industry Insights Download Free Report

Drugs Made In America Acquisition II Corp. Ordinary Shares

Company price
10.245 USD 0.01 ( 0.05%)
Last update at 2026-11-17T21:00:00Z
VOLUME
6734
Market Cap
637.64M
P/E
66.73

Momentum Score

…

Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
10.24
Low
10.24
High
52 Week Price Range
9.86
Low
10.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Drugs Made In America Acquisition II Corp. is a special-purpose acquisition company formed to identify and combine with a business and appears focused on U.S.-based pharmaceutical manufacturing and supply-chain onshoring. Long-term growth drivers may include rising demand for domestic drug production, potential government support for supply-chain resilience, and consolidation opportunities in contract manufacturing, which could make the SPAC a way to gain thematic exposure without selecting an operating company.

Principal risks include absence of operating history prior to a business combination, reliance on completing a value-accretive merger within the SPAC's timeframe, sponsor conflicts and shareholder dilution, and sector-specific regulatory, capital-intensity and execution risks for any acquired target.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
10.24
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.81M
Debt / Equity
-2.14
ROE
-
Net Debt
-0.00M
ROCE
-0.26%
Diluted EPS TTM
0.15

Insight Announcement

DMII Proposes $600M Deal With Alpha AI Biotech

Manish Choudhary | 35 minutes ago
View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Income before tax 4.19M -0.15M
Net income 4.19M -0.15M
Selling general administrative 0.49M -
Ebitda -1.30M -0.15M
Operating income -1.30M -0.15M
Other operating expenses 1.30M 0.15M
Interest income 4.93M -
Net interest income 4.93M -
Total revenue 0.00M -
Total operating expenses 1.30M 0.15M
Total other income expense net 5.49M -
Net income from continuing ops 4.19M -
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Total assets 504.96M 0.14M
Other current assets 0.03M 0.04M
Total liab 17.80M 0.25M
Total stockholder equity 487.16M -0.12M
Other current liab 0.20M 0.00M
Common stock 504.94M 0.00M
Capital stock 504.94M 0.00M
Retained earnings -17.78M -0.15M
Cash 0.00M 0.02M
Total current liabilities 0.30M 0.25M
Net debt -0.00M 0.23M
Short term debt - 0.25M
Short long term debt - 0.25M
Short long term debt total - 0.25M
Other stockholder equity - 0.03M
Total current assets 0.03M 0.06M
Accounts payable 0.10M 0.00M
Non currrent assets other 504.93M 0.08M
Non current assets total 504.93M 0.08M
Breakdown 2025-12-31 2024-12-31
Type yearly yearly
Date 2025-12-31 2024-12-31
Investments -500.00M -
Total cashflows from investing activities -500.00M -
Net borrowings -0.53M -
Total cash from financing activities 501.00M 0.21M
Net income 4.19M -0.15M
Change in cash -0.02M 0.02M
Begin period cash flow 0.02M -
End period cash flow 0.00M 0.02M
Total cash from operating activities -1.02M -0.19M
Issuance of capital stock 502.00M -
Other cashflows from investing activities -500.00M -
Change to account receivables -0.81M -
Other cashflows from financing activities 501.00M -
Capital expenditures 0.00M 0.00M
Change in working capital -0.61M -0.04M
Other non cash items -4.60M -
Free cash flow -1.02M -0.19M

Peer Comparison*

Sector: Financial Services Industry: Shell Companies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
DMII
Drugs Made In America Acquisition II Corp. Ordinary Shares
0.01
0.05%
10.24 66.73 - - 1.31
CLUS
CLUS
-
-%
200.00 - - 0.09 0.92
SGDH
Sgd Holdings Ltd
-
-%
0.02 - - 59741.55 0.56
LION
Lionsgate Studios Holding Corp.
0.11
0.80%
13.85 - 23.31 1.13 1.35
QKIE
QKIE
-
-%
1.94 - - 470.20 -

Profile*

Drugs Made In America Acquisition II Corp. Ordinary Shares

Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.

1 East Broward Boulevard, Fort Lauderdale, FL, United States, 33301

954 870 3099

Name Title Year Born
Mr. Roger Bendelac Chief Executive Officer 1957

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…